HOW TO TAKE THE POST-TEST: To obtain CME credit, please click here after reading the article to take the post-test on myCME.com. Organ transplantation has become a fairly common and effective modality ...

In a new study, researchers from France have revealed why people with neurofibromatosis type 1 (NF1) often develop serious ...

Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed to reduce the number of fractures per year, sending its shares plunging 43.5% ...

Ultragenyx Pharmaceutical said on Monday late-stage studies showed its experimental drug for a type of genetic bone disease failed to reduce the number of fractures that occurred per year. Shares of ...

Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions worldwide, often causing chronic pain and disability. These disorders stem from ...

Studies by University of Birmingham researchers suggest that a naturally occurring peptide known as PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration), could represent a promising potential ...

Scientists uncovered how the protein Piezo1 translates physical activity into stronger bones, offering a path to ...

A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone disease, setrusumab, failed a pair of phase 3 trials.